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Abstract Given that goat milk and dairy products should be consumed daily according
to suggestions based on Mediterranean diet, the current study evaluates the anti-
atherogenic properties of goat milk and goat dairy products (yogurt and white cheese).
Total lipids (TLs) of all three samples were extracted by the method of Bligh and Dyer
and further separated into total polar lipids (TPLs) and total neutral lipids (TNLs) by
counter current distribution. The fatty acid profiles of TPL and TNL of all three
samples were determined by gas chromatography analysis. TL and TPL were tested
to determine whether they induce platelet aggregation or inhibit platelet aggregation
induced by the platelet-activating factor (PAF). The most active lipids were found in
goat white cheese (i.e., since they showed lower IC50 values in both TL and TPL
samples than corresponding fractions of goat milk and goat yogurt), so the TPL of goat
white cheese were further separated by preparative thin-layer chromatography (TLC).
The obtained polar lipid fractions after TLC separation were also tested for their
biological activity. All the samples’ lipids, and especially the polar ones, were found
to exhibit strong anti-atherogenic activities. This fact highlights the nutritional value of
goat dairy products in terms of cardioprotection, as PAF is a crucial inflammatory
mediator that is implicated in the mechanism of atherogenesis.
Keywords Goat . Platelet-activating factor (PAF) . Polar lipids . Atherosclerosis .
Platelets
Dairy Sci. & Technol. (2016) 96:317–327
DOI 10.1007/s13594-015-0266-x
* Ioannis Zabetakis
izabet@chem.uoa.gr
1 Laboratory of Food Chemistry, Department of Chemistry, National and Kapodistrian University of
Athens, 15771 Athens, Greece
2 Department of Food Science and Nutrition, School of the Environment, University of the Aegean,
Myrina, Lemnos 81400, Greece
1 Introduction
The Mediterranean diet has been linked with a protective role against chronic diseases,
mainly cardiovascular diseases (CVDs) and cancer (Panagiotakos et al. 2005). Milk
and dairy products are important components of the Mediterranean diet (Selvaggi et al.
2014), and it is proposed that they be consumed daily (Kastorini et al. 2010).
Additionally, dairy products (i.e., yogurt and cheese) have been shown more benefi-
cially effective against atherogenesis and CVDs than milk (Tsorotioti et al. 2014). This
has been attributed to the fact that the microorganisms Streptococcus thermophilus and
Lactobacillus bulgaricus, that are involved in the fermentation of yogurt and cheese,
have been found to aid the bioformation of lipids that inhibit PAF-induced platelet
activation (Antonopoulou et al. 1996).
Platelet-activating factor (PAF) (1-O-alkyl-2-acetylsn-glyceryl-3-phosphocholine) is
a crucial inflammatory phospholipid mediator (Demopoulos et al. 1979) that is impli-
cated in the mechanism of atherogenesis (Demopoulos et al. 2003). According to this
mechanism, PAF is produced during low-density lipoprotein (LDL) oxidation
(Liapikos et al. 1994) and causes in situ inflammation. PAF is a compound of
atheromatic plaque and is essential for the activation of leukocytes and their binding
to endothelial cells (Nasopoulou et al. 2013).
Goats (meat, milk, and dairy products) have lately been at the center of attention due
to the increasing interest in the nutritional value of their products (Park and Haenlein
2013). There is also an increasing need to consume goat milk, as a growing part of the
population suffer from intolerance and allergy to other types of milk, such as cow milk
(Selvaggi et al. 2014).
Goat milk consumption, compared to that of cow milk, decreases plasma cholesterol
concentration. Moreover, consumption of this type of milk decreases the plasma
concentration of triglycerides and therefore has a positive effect, similar to that of
virgin olive oil (López-Aliaga et al. 2005).
Goat milk is a reliable source of high-quality protein (Raynal-Ljutovac et al. 2008)
and has higher protein and fat digestibility than cow milk (Sanz Ceballos et al. 2009)
(López-Aliaga et al. 2010). Fat high digestibility is due to smaller fat globule size and
higher contents of short- and medium-chain fatty acids. The smaller-sized fat globules
result in a better dispersion and a more homogeneous mixture of fat in the milk, and the
larger surface/volume ratio of the fat globules enhances further pancreatic lipase
activity, making goat milk easier to digest (López-Aliaga et al. 2010).
The prevention of cardiovascular diseases (CVDs) and atherosclerosis, in particular,
is a major objective of research in life sciences (Zabetakis 2013). The aim of the current
study is, thus, to determine the activities of goat milk and related dairy products against
atherogenesis and therefore the onset of CVDs.
2 Materials and methods
2.1 Reagents and instruments
All reagents and solvents were of analytical grade purchased from Merck (Darmstadt,
Germany). Fatty acid methyl ester standards bought individually were of GC-quality
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and supplied by Sigma-Aldrich (St. Louis, MO, USA), as well as bovine serum
albumin (BSA) and PAF.
Chromatographic material used for thin-layer chromatography (TLC) was silica gel
G-60 supplied by Merck (Darmstadt, Germany) and polar lipid standards used for TLC
was a standard mix of hen egg yolk supplied by Sigma-Aldrich (St. Louis, MO, USA).
Platelet aggregation was measured in a Chrono-Log (Havertown, PA, USA)
aggregometer (model 400-VS) coupled to a Chrono-Log recorder (Havertown, PA,
USA).
2.2 Samples of goat milk and goat dairy products
Three different samples of goat products (milk, yogurt, and white cheese) were
purchased from the local market.
2.3 Isolation of lipids
Total lipids (TLs) were extracted from 200 g of each sample (goat milk, goat yogurt,
and goat white cheese) according to the Bligh-Dyer method (Bligh and Dyer 1959).
One tenth of the TL was weighed and stored in sealed vials under nitrogen atmosphere
at −20 °C until used, while the rest of it was further separated into total polar lipids
(TPL) and total neutral lipids (TNL) by countercurrent distribution chromatography
(Galanos and Kapoulas 1962). In brief, TLs were mixed with pre-equilibrated solvents:
petroleum ether and 87% aqueous ethanol in ratio 3:1 (v/v). The obtained biphasic
solvent system contained TPL distributed in the ethanol phase and TNL distributed in
the petroleum ether phase.
The experimental procedure is as follows: petroleum ether and 87% aqueous ethanol
were pre-equilibrated in a separatory funnel. The lower phase containing equilibrated
87% ethanol and the upper phase containing equilibrated petroleum ether were collect-
ed separately. An amount of dry TL was dissolved in 9 mL pre-equilibrated petroleum
ether and then 3 mL pre-equilibrated 87% ethanol were added and stirred. The lower
phase, which is the ethanol phase, was collected and transferred to second test tube
containing 9 mL pre-equilibrated petroleum ether and was stirred again. Ethanolic
phase was then transferred to a third empty test tube. The procedure was repeated eight
times in total. Finally, the ethanolic phase (8×3 mL), containing TPL, and the phase of
petroleum ether (2×9 mL), containing TNL, were evaporated to dryness, weighed,
redissolved in chloroform: methanol in ratio 1:1 (v/v), and stored under nitrogen in
sealed vials at −20 °C until used—after a short period of time—for further analysis.
TPL of goat white cheese were further separated by preparative TLC. All TLC lipid
fractions obtained were stored under nitrogen atmosphere at −20 °C for further
analysis.
2.4 Fractionation of TPL by preparative TLC
The TLC glass plates (20×20 cm) were coated with silica gel G-60 and activated by
heating at 120 °C for 60 min. The thickness of the TLC plates was 1.0 mm (preparative
TLC). Approximately, 50 mg of TPL of the white cheese was applied to the TLC
plates. A developing system consisting of chloroform/methanol/water 65:35:6 (v/v/v)
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was used. The plates were stained under iodine vapors. Seven bands appeared after the
separation of TPL of the white cheese sample. After staining of the TLC plate with
iodine vapors, the bands were scraped off, and lipids were extracted from silica gel
according to the Bligh-Dyer method (Bligh and Dyer 1959). The chloroform phase was
evaporated to dryness under nitrogen, and lipids were weighed, redissolved in 1 mL
chloroform/methanol 1:1 (v/v), and stored at −20 °C.
2.5 Biological assay on washed rabbit platelets
TL and TPL of all samples, and purified polar lipid fractions of the white cheese,
obtained by the above TLC separation, were tested for their biological activity accord-
ing to the washed rabbit platelet assay (Demopoulos et al. 1979). Briefly, all examined
samples and PAF were dissolved in 2.5 mg BSA mL−1 saline (0.90% w/v NaCl).
Serially increasing amounts of the examined sample were added into the aggregometer
cuvette, and their ability to aggregate washed rabbit platelets and/or to inhibit PAF-
induced platelet aggregation was determined. Washed rabbit platelet concentration was
approximately 500,000 platelets μL−1. In order to determine the aggregatory efficiency
of either PAF or the examined samples, the maximum reversible PAF-induced aggre-
gation was evaluated, and the 100% aggregation point was determined. The plot of the
percentage of the maximum reversible aggregation (ranging from 20 to 80%) versus
different concentrations of the aggregatory agent was linear. From this curve, the
concentration of the aggregatory agent, which induces 50% of the maximum reversible
PAF-induced aggregation, was calculated. This value is defined as the amount of the
sample that induces an equivalent to PAF EC50, namely equivalent concentration for
50% aggregation.
In order to determine the inhibitory properties of the samples’ lipids, serially
increasing amounts of the lipids being examined were added into the
aggregometer cuvette, and their ability to inhibit PAF-induced aggregation was
determined. The platelet aggregation induced by PAF (29.59×10−11 M, final
concentration in the cuvette) was measured as PAF-induced aggregation in washed
rabbit platelets before (considered as 0% inhibition) and after the addition of
various amounts of the sample being examined. Consequently, the plot of percent
inhibition (ranging from 20 to 80%) versus different concentrations of the sample
is linear. From this curve, the concentration of the sample, which inhibited 50%
the PAF-induced aggregation, was calculated. This value is defined as IC50,
namely inhibitory concentration for 50% inhibition.
2.6 Gas chromatographic analysis
Fatty acid methyl esters (FAME) of 35 mg of TPL and 35 mg of TNL of all three
samples were prepared using a solution of 0.5 N KOH in CH3OH (KOH-CH3OH
method, reaction time 5 min) and extracted with n-hexane. The fatty acid analysis
was carried out using the internal standard method (Nasopoulou et al. 2011). A
five-point calibration curve was prepared using five solutions of heptadecanoic
(17:0) acid methyl ester and heneicosanoic (21:0) acid methyl ester in ratios of
1000:2000 (v/v), 1000:1000 (v/v), 1000:400 (v/v), 1000:200 (v/v), and 1000:100
(v/v), respectively. Five injections of 1 μL of each solution were analyzed with a
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Shimadzu CLASS-VP (GC-17A) (Kyoto, Japan) gas chromatograph equipped
with a split/splitless injector and flame ionization detector. The ratio of the mean
area of heneicosanoic to that of the internal standard (heptadecanoic) was used as
the y-axis variable of the calibration curve, while the concentration (mg.kg−1) of
heneicosanoic was used as the x-axis variable of the calibration curve. The
equation that described the calibration curve was y = 0.00012x + 0.0167 with
r=0.99993.
The ratio of the area of the analyte peak to that of the internal standard represented
the y value in the above equation, and subsequently, the x value represented the analyte
concentration of the fatty acid in the unknown mixture. Separation of fatty acid methyl
esters was achieved on an Agilent J&W DB-23 fused silica capillary column (60 m×
0.251 mm i.d., 0.25 μm; Agilent, Santa Clara, CA, USA). The oven temperature value
sequence was initially 120 °C for 5 min, raised to 180 °C at 10 °C min−1, then to
220 °C at 20 °C min−1, and finally isothermal at 220 °C for 30 min. The injector and
detector temperatures were maintained at 220 and 225 °C, respectively. The carrier gas
was high purity helium with a linear flow rate of 1 mL.min−1 and split ratio of 1:50.
Fatty acid methyl esters were identified using Supelco 37-Component FAME Mix in
dichloromethane.
2.7 Statistical analysis
All experiment analyses were carried out in triplicate, and all results were expressed as
mean value±SD. One-way analysis of variance (ANOVA) was used in order to find the
statistically significant differences. Differences were considered to be statistically
significant when p was lower than 0.05. The data were analyzed using a statistical
software package (PASW 18 for Windows, SPSS Inc., Chicago, IL, USA).
3 Results
3.1 TL, TPL, and TNL contents of goat milk, goat yogurt, and goat white cheese
samples
The amount of TL, TPL, and TNL of all three samples are shown in Table 1. The yield
of the total lipid extraction was found to be 70%. TPL and TNL profiles (both
expressed as %TL) of all three samples were found to be similar (p>0.05).
Table 1 Content of total lipids (TL), expressed in grams per 100 g sample (mean±SD, n=3), total polar lipids
(TPL), and total neutral lipids (TNL), expressed as percentages of TL in goat milk, goat yogurt, and goat white
cheese
Samples TL (g/100 g sample) TPL (% TL) TNL (% TL)
Goat milk 2.18 5.81 87.9
Goat yogurt 2.60 5.78 90.9
Goat white cheese 17.1 6.19 87.8
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3.2 Fatty acid profiles of TPL and TNL of goat milk, goat yogurt, and goat white
cheese samples
The fatty acid profiles of TPL and TNL of all three samples are presented in Tables 2
and 3, respectively. Significant amounts of saturated fatty acids 6:0, 10:0, 12:0, 14:0,
16:0, and 18:0 have been detected, along with the monounsaturated fatty acid 18:1 cis
(ω-9) and the polyunsaturated fatty acids 18:2 (ω-6) and 18:3 (ω-3), in both TPL and
TNL fractions. The fatty acid profiles of goat milk, goat yogurt, and goat white cheese
exhibited statistical significant differences (Tables 2 and 3). Goat white cheese was
found to contain statistical significant increased levels of all detected fatty acids in
comparison to the ones of goat milk and goat yogurt, which is reasonable due to the
higher content of fat per kilogram of goat white cheese than goat milk and yogurt. Fatty
acid profile and generally the composition of goat milk and its products are influenced
by several factors such as breed, age, genotype, feed, environment, season, and
technology (Raynal-Ljutovac et al. 2008).
3.3 Biological activity of TL, TPL of all three samples
The extracted TL and TPL of each sample were tested for their ability to induce washed
rabbit platelet aggregation or inhibit PAF-induced platelet aggregation. When they
induce platelet aggregation, they act like PAF, but they are thousands of times less active
than PAF, thus they are practically acting as PAF inhibitors (Nasopoulou et al. 2013).
These PAF-agonists (with PAF-like activity) have been found to have better in vivo anti-
atherogenic activity than PAF inhibitors (Tsantila et al. 2007) (Nasopoulou et al. 2010).
Table 2 Fatty acid profile of to-
tal polar lipids (TPL) of each
sample expressed in milligrams
per kilogram of sample (mean±
SD, n=3)
Fatty acids Goat milk Goat yogurt Goat white cheese
6:0 8.66±2.35a, b 14.1±1.02a, c 39.3±2.62b, c
8:0 ND ND ND
10:0 11.5±0.63a, b 6.52±0.11a, c 108±0.18b, c
12:0 6.16±0.22a, b 7.01±0.16a, c 60.2±4.61b, c
14:0 15.5±0.05a, b 19.7±0.17a, c 134±2.54b, c
15:0 0.18±0.02a, b 0.34±0.03a, c 5.12±0.43b, c
16:0 45.2±0.45a, b 64.4±0.86a, c 373±0.34b, c
16:1 (ω-7) 0.55±0.09a, b 0.39±0.04a, c ND
18:0 24.3±0.56a, b 41.2±0.29a, c 217±19.4b, c
18:1 cis (ω-9) 58.0±0.07a, b 94.0±0.47a, c 447±17.1b, c
18:2 (ω-6) 10.4±0.14a, b 17.2±0.25a, c 64.1±0.72b, c
18:3 (ω-3) 0.76±0.03a, b 1.44±0.05a, c 15.0±0.23b, c
ND Non-detectable
a Indicates statistical significance between goat milk and goat yogurt
(p<0.05), according to ANOVA analysis
b Indicates statistical significance between goat milk and goat white
cheese (p<0.05), according to ANOVA analysis
c Indicates statistical significance between goat yogurt and goat
white cheese (p<0.05), according to ANOVA analysis
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The biological activities of TL and TPL of each sample expressed in micro-
grams are shown in Fig. 1. For the comparison of IC50 values, we should
mention that a lower IC50 value corresponds to a smaller amount of lipids needed
for the same biological activity. So, a lower IC50 value is preferable. For the
comparison of EC50 values, the opposite applies, i.e., a higher EC50 value is
preferable, corresponding to a higher amount of lipids needed for 50% PAF-like
aggregation.
According to Fig. 1, TL and TPL exhibited inhibitory activity toward PAF-induced
platelet aggregation, while none of the TL or TPL have shown PAF-like aggregatory
activity. Additionally, TL of goat white cheese sample had a significantly lower
(p<0.05) IC50 value compared to TL of the other two samples. Also, TL of goat yogurt
sample had significantly lower (p<0.05) IC50 value compared to TL of goat milk
sample. TPL of goat milk and goat white cheese samples appeared to have similar IC50
values (p>0.05), but they were found to be significantly lower (p<0.05) than goat
yogurt’s IC50 value.
3.4 Biological activity of TLC polar lipid fractions from goat white cheese sample
TPL of goat white cheese were further separated with preparative TLC and seven polar
lipid fractions were obtained (Fig. 2).
TLC polar lipid fractions of goat white cheese were found to exhibit strong
inhibitory activity toward PAF (Fig. 3). TLC polar lipid fractions with the most
potent anti-PAF properties were found to be lipid fractions 3 (Rf value similar to
Table 3 Fatty acid profile of to-
tal neutral lipids (TNL) of each
sample expressed in milligrams
per kilogram of sample (mean±
SD, n=3)
Fatty acids Goat milk Goat yogurt Goat white
cheese
6:0 83.5±3.87a, b 114±7.02a, c 584±19.1b, c
8:0 ND ND ND
10:0 245±13.8a, b 300±16.2a, c 1529±22.3b, c
12:0 137±6.74a, b 165±7.16a, c 808±10.5b, c
14:0 367±10.7a, b 453±9.63a, c 1878±21.2b, c
15:0 11.9±0.39a, b 14.7±1.08a, c 69.2±1.91b, c
16:0 1112±10.6a, b 1373±21.2a, c 5253±49.8b, c
16:1 (ω-7) 3.13±0.80a, b 3.86±0.99a, c ND
18:0 609±4.00a, b 751±5.29a, c 2885±38.6b, c
18:1 cis (ω-9) 927±4.76a, b 1145±6.32a, c 6507±51.3b, c
18:2 (ω-6) 85.8±0.57a, b 105±1.55a, c 916±14.1b, c
18:3 (ω-3) 13.0±0.09a, b 16.0±0.13a, c 215±9.50b, c
ND Non-detectable
a Indicates statistical significance between goat milk and goat yogurt
(p<0.05), according to ANOVA analysis
b Indicates statistical significance between goat milk and goat white
cheese (p<0.05), according to ANOVA analysis
c Indicates statistical significance between goat yogurt and goat
white cheese (p<0.05), according to ANOVA analysis
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that of phosphatidylcholine—PC), 5 (Rf value similar to that of phosphatidyleth-
anolamine—PE), and 6, which had similar IC50 values (p>0.05). The IC50 values
of these three lipid fractions were also significantly lower (p<0.05) when com-
pared to the IC50 values of the rest TLC polar lipid fractions. Also, polar lipid
fraction 2 was the only fraction that was found to have a PAF-like aggregatory
activity (EC50 value). This polar lipid fraction had similar Rf value to that of
sphingomyelin (SM).
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Fig. 1 In vitro biological activity of total lipids (TL) and total polar lipids (TPL) of goat milk, goat yogurt, and
goat white cheese samples toward washed rabbit platelet aggregation, expressed in micrograms
Fig. 2 Preparative TLC plate of goat white cheese sample (stained under iodine vapors). In the photo, the nine
bands obtained are shown on the right, whereas on the left, the corresponding elution fronts of standard
compounds is given. L-PC lyso-phosphatidylcholine, SM sphingomyelin, PC phosphatidylcholine, L-PE lyso-
phosphatidylethanolamine, PE phosphatidylethanolamine, CL cardiolipin
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4 Discussion
Our results have demonstrated that TL from goat samples (milk, yogurt, and white
cheese) contains PAF inhibitors. TL of goat white cheese and goat yogurt appeared to
exhibit stronger anti-atherogenic activities which could be attributed to the fact that
microorganisms, such as S. thermophilus and L. bulgaricus, that are involved in the
fermentation of yogurt and cheese, have been found to aid the formation of lipids that
inhibit PAF-induced platelet activation (Antonopoulou et al. 1996). According to our
results, these PAF inhibitors are mainly present in the TPL fraction.
Further fractionation of TPL from goat white cheese sample by preparative TLC and
biological assay of the seven polar lipid fractions obtained showed that polar lipid
fractions with Rf values similar to those of SM, PC, and PE exhibited strong biological
activity. Those phospho- and sphingolipids are present in various dairy products
(Rombaut et al. 2007).
The presence of PAF inhibitors in various foods is very important in terms of their
capacity to prevent the onset of CVDs and thus this parameter affects their overall
nutritional value (Nomikos et al. 2007). Lipid microconstituents of specific foods
animal-origin, i.e., cheese (Tsorotioti et al. 2014) and eggs (Nasopoulou et al. 2013),
that constitute important ingredients of the Mediterranean diet, have been found to exert
in vitro important biological activities by inhibiting PAF actions. These lipid
microconstituents could inhibit the onset of the atherosclerosis and the development
of CVDs, as several in vivo studies have shown (Karantonis et al. 2006; Tsantila et al.
2007; Nasopoulou et al. 2010; Tsantila et al. 2010).
5 Conclusion
In conclusion, our results underline the nutritional value of goat milk, yogurt, and white
cheese and demonstrate that the TL and the TPL of all three products appeared to have
inhibitory activities against PAF-induced platelet activation. The novelty of this work is
on the comparison of these anti-atherogenic activities; the three products in terms of
increased cardioprotection could be classified as milk<yogurt<white cheese. It could be
thus interpreted that the regular consumption of these dairy foods offers anti-
Fig. 3 In vitro biological activity of preparative thin-layer chromatography (TLC) polar lipid fractions of goat
white cheese sample toward washed rabbit platelet aggregation, expressed in micrograms
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atherogenic protection and therefore protection against the development of CVDs.
Future dietary guidelines should take into account data like the ones presented here
when redefining the suggested consumption (frequency and servings per day) of dairy
products, especially the ones originated from goat milk.
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